Cost Analysis of Psoriasis Treatment Modalities in Malaysian Public Hospitals
Cost Analysis of Psoriasis Treatments
Vol. 14 No. 1 : 2019 (23-33)
Abstract
Psoriasis imposes a great economic burden as a result of higher expenditures for different interventions, diagnostic procedures, pharmaceuticals and loss of productivity. Less is known about the economic impact of psoriasis treatment in Asean region. The aim of this research was to calculate the costs associated with four psoriasis treatment modalities. A prospective cohort study was conducted in five hospitals involving 91 moderate to severe psoriasis patients. Costs were calculated from the societal perspective using the principle of Step Down and Activity Based Costing (ABC) within a six (6) months follow-up duration. The components of the costs borne by the provider were inpatient cost, cost of medication, laboratory investigation and radiology. Patient’s cost included out of pocket expenses, travelling cost and loss of productivity. Cost per patient per day was RM1,105.24 (inpatient) (US$315.94) and RM298.02 (outpatient) (US$85.19). Medication accounted for almost 90% (RM457,014.00) (US$130 638.45) of the total provider cost. Meanwhile, loss of productivity represented 84% (RM167,439.00) (US$47,862.80) of the total patient’s cost. Biologic treatment exhibited the highest cost which was RM342,377.00 (US$97,869.21), followed by systemic treatment (RM105,607.00) (US$30,187.99), topical treatment (RM38,280.00) (US$10,942.42) and topical phototherapy treatment (RM21,824.00) (US$6,238.44). Understanding the relationship between direct and indirect costs from both perspectives is important to accurately identify and evaluate effective treatment for psoriasis.
Keywords :
cost analysis,
Malaysia,
psoriasis,
Correspondance Address
Aniza binti Ismail. Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia. Tel: +603-91455913 E-mail: draniza@gmail.com
References
Augustin, M., Krüger, K., Radtke, M.A., Schwippl, I., Reich, K. 2008. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 216(4): 366-72.
Balogh, O., Brodszky, V., Gulácsim L., Herédi, E., Herszényi, K., Jókai, H., Kárpáti, S., Baji, P., Remenyik, É., Szegedi, A., Holló, P. 2014. Cost-of-Illness in Patients with Moderate to Severe Psoriasis: A Cross-Sectional Survey in Hungarian Dermatological Centres. Eur J Health Econ 15(1): 101-9.
Beyer, V., Wolverton, S.E. 2010. Recent Trends in Systemic Psoriasis Treatment Costs. Arch Dermatol 146(1): 46-54.
Chen, K.C., Hung. S.T., Yang, C.W., Tsai, T.F., Tang C.H. 2014. The Economic Burden of Psoriatic Diseases in Taiwan. J Dermatol Sci 75(3): 183-9.
Cheng, J., Feldman, S.R. 2014. The Cost of Biologics for Psoriasis Is Increasing. Drugs in Context 3: 212266.
Colombo, G., Altomare, G., Peris, K., Martini, P., Quarta, G., Congedo, M. Costanzo, A., Di Cesare, A., Lapucci, E., Chimenti, S. 2008. Moderate and Severe Plaque Psoriasis: Cost-of-Illness Study in Italy. Ther Clin Risk Manag 4(2): 559-68.
Crown, W. H., Bresnahan, B. W., Orsini, L. S., Kennedy, S. & Leonardi, C. 2004. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin 20(12): 1929-36.
de Arruda, L.H., De Moraes, A.P. 2001. The Impact of Psoriasis on Quality of Life. Br J Dermatol 144(Suppl 58): 33-6.
Drummond, M.F., Sculpher, M., Claxton, K., Stoddart, G.L., Torrance, G. 2015. Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford University Press.
Ellis, C., Barker, J. 2000. Psoriasis: A View for the Year 2000. Curr Probl Dermatol 12(2): 45-50.
Ferrándiz, C., Carrascosa, J.M., Boada, A. 2010. A New Era in the Management of Psoriasis? The Biologics: Facts and Controversies. Clin Dermatol 28(1): 81-7.
Gospodarevskaya, E., Picot, J., Cooper, K., Loveman, E., Takeda, A. 2009. Ustekinumab for the Treatment of Moderate to Severe Psoriasis. Health Technol Assess 13(3): 61-6.
Ismail, A., Sulong, S., Zafar, A., Syed Junid, S. M. A-J., Wan Norlida, I., Maskon, O., Che Hassan, H. H. 2016. Implementation of clinical pathways in Malaysia: Can clinical pathways improve the quality of care? Int Med J 23(1): 47-50.
Langan, S.M., Heerey, A., Barry, M., Barnes, L. 2004. Cost analysis of narrowband uvb phototherapy in psoriasis. J Am Acad Dermatol 50(4): 623-6.
Levy, A.R., Davie, A.M., Brazier, N.C., Jivraj, F., Albrecht, L.E., Gratton, D., Lynde, C.W. 2012. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol 51(12): 1432-40.
Mantovani, L., Medaglia, M., Piacentini, P., Tricca, M., Vena, G.A., Vozza, A., Castellino, G. 2016. Burden of moderate-to-severe plaque psoriasis and new therapeutic approaches (Secukinumab): an italian perspective. Dermatol Ther 6(2): 151-67.
Mattila, K., Leino, M., Mustonen, A., Koulu, L., Tuominen, R. 2013. Influence of psoriasis on work. Eur J Dermatol 23(2): 208-11.
Ministry of Health. 2013. Clinical Practice Guidelines: Management of Psoriasis Vulgaris http://www.moh.gov.my/penerbitan/CPG2017/9004.pdf [22 September 2014]
Morrow, T. 2006. Cost-effective psoriasis treatment may demand creative coverage rules. Manag Care 15(5): 61-3.
Mustonen, A., Leino, M., Mattila, K., Koulu, L., Tuominen, R. 2014. Treatment costs of psoriasis in a tertiary-level clinic. BMC Health Serv Res 14(1): 344.
Obradors, M., Figueras, M., Paz, S., Comellas, M., Lizán. L. 2014. Costs of psoriasis in Europe. A systematic review of the literature. Value Health 17(7): A606.
Pearce, D.J., Nelson, A.A., Fleischer, A.B., Balkrishnan, R., Feldman, S.R. 2006. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatolog Treat 17(1): 29-37.
Raho, G., Koleva, D.M., Garattini, L., Naldi, L. 2012. The burden of moderate to severe psoriasis: an overview. PharmacoEconomics 30(11): 1005-13.
Schmitt, J.M., Ford, D.E. 2006. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 213(2): 102–10.
Sharifah Ezat, W.P., Azimatun, N., Amrizal, M., Rohaizan, J., Saperi, S. 2009. Economic burden of diabetic care in government health facilities in Selangor. Journal of Community Health 15(2): 17-26.
Sohn, S., Schoeffski, O., Prinz, J., Reich, K., Schubert, E., Waldorf, K., Augustin, M. 2006. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 212(2): 137-44.
Steinke, S.I., Peitsch, W.K., Ludwig, A., Goebeler, M. 2013. Cost-of-illness in psoriasis: comparing inpatient and outpatient therapy. PLoS One 8(10): e78152.
Stern, R.S., Nijsten, T., Feldman, S.R., Margolis, D.J., Rolstad, T. 2004. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 9(2): 136-9.
Sulong, S., Ismail, A., Azizam, N.A., Md Nor, N., Ahmed, Z. 2016. Economic burden and cost effectiveness analysis of psoriasis treatment modalities in Malaysian public hospitals : a study protocol. The European Proceedings of Social and Behavioural Sciences 243-50
Tang, M.M., Chang, C.C., Chan, L.C., Heng, A. 2013. Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study. Int J Dermatol 52(3): 314-22.
Vanderpuye-Orgle, J., Zhao, Y., Lu, J., Shrestha, A., Sexton, A., Seabury, S., Lebwohl, M. 2015. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol 72(6): 961-7.
Vañó-Galván, S., Gárate, M.T., Fleta-Asín, B., Hidalgo, A., Fernández-Guarino, M., Bermejo, T., Jaén, P. 2012. Analysis of the cost effectiveness of home-based phototherapy with narrow-band uv-b radiation compared with biological drugs for the treatment of moderate to severe psoriasis. Actas Dermosifiliogr 103(2): 127-37.
